Press Releases

 "PRM-151 will complement our growing early-stage fibrosis portfolio, and we are excited by its potential to address multiple fibrotic diseases." Bristol-Myers Squibb Company (NYSE:BMY) and Promedior, Inc. announced the companies have entered into an agreement that...

 "We are excited to work with QIMR Berghofer Medical Research Institute, a partner that brings significant experience and expertise in cancer research." Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research...

Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Richard Gaynor, M.D., senior vice president of product...

This acceptance for review marks the first in the U.S. for a SLAMF7-directed immunostimulatory antibody   "AbbVie is encouraged by the FDA’s decision to award priority review to this application" Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie...

  The checklist, now in its ninth year, is a direct result of post-Katrina learnings ,For Sherry Martin, M.D., starting her new job at Eli Lilly and Company (NYSE: LLY) in August 2005 was stressful enough. ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). ...

Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant...